Relay Therapeutics (RLAY) Stock Forecast & Price Target

$5.60 -0.21 (-3.61%)

(As of 11/14/2024 ET)

Relay Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
1

Buy
9

Based on 10 Wall Street analysts who have issued ratings for Relay Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for RLAY.

Consensus Price Target

$21.22
278.97% Upside

According to the 10 analysts' twelve-month price targets for Relay Therapeutics, the average price target is $21.22. The highest price target for RLAY is $28.00, while the lowest price target for RLAY is $16.00. The average price target represents a forecasted upside of 278.97% from the current price of $5.60.

Get the Latest News and Ratings for RLAY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Relay Therapeutics and its competitors.

RLAY Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$21.22	$21.11	$21.67	$24.83
Forecasted Upside	278.97% Upside	210.46% Upside	235.92% Upside	208.11% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

RLAY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RLAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Relay Therapeutics Stock vs. The Competition

Type	Relay Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	278.97% Upside	26,222.84% Upside	8.87% Upside
News Sentiment Rating	Positive News See Recent RLAY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$19.00 ➝ $20.00	+226.80%
9/17/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00 ➝ $21.00	+164.82%
9/16/2024	Stifel Nicolaus 4 of 5 stars		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+250.00%
9/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$20.00 ➝ $24.00	+180.70%
9/10/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$14.00 ➝ $17.00	+97.90%
9/10/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$23.00 ➝ $21.00	+144.47%
Get the Latest News and Ratings for RLAY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/10/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00	+110.30%
9/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
9/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$10.60 ➝ $16.00	+68.24%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
4/19/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Outperform ➝ Strong-Buy	$29.00	+149.57%
3/9/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$45.00 ➝ $28.00	+65.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:35 AM ET.

RLAY Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Relay Therapeutics is $21.22, with a high forecast of $28.00 and a low forecast of $16.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLAY shares.
: According to analysts, Relay Therapeutics's stock has a predicted upside of 278.97% based on their 12-month stock forecasts.
: Over the previous 90 days, Relay Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.
: Relay Therapeutics has been rated by research analysts at Bank of America, Barclays, HC Wainwright, Jefferies Financial Group, JMP Securities, JPMorgan Chase & Co., Oppenheimer, Stifel Nicolaus, and The Goldman Sachs Group in the past 90 days.
: Analysts like Relay Therapeutics more than other "medical" companies. The consensus rating score for Relay Therapeutics is 2.90 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RLAY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Crypto’s Hidden Gem: The missing piece no one’s talking about (Ad)

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem

This page (NASDAQ:RLAY) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Stock Forecast & Price Target